John T. Brooks

John T. Brooks

Auto-generated profile, based on publicly available information

John T. Brooks

Division of HIV Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ASAdam Sherwat
Adam Sherwat
JBJohn T. Brooks
John T. Brooks
DBDebra Birnkrant
Debra Birnkrant
PKPeter Kim
Peter Kim
In 1988, the human immunodeficiency virus (HIV) was rapidly spreading worldwide and disproportionately devastating certain communities, most notably gay, bisexual, and other men who have sex with men. Even after promising new pharmacologic therapies were finally developed, the existing processes for approving their use in humans were painfully slow. Spurred by the AIDS Coalition to Unleash Power (ACT UP) and other advocacy groups, federal scientists and policymakers worked with affected persons to find a way forward that balanced two ethical imperatives: honoring the right of people with serious illness to access potentially beneficial treatment and upholding the responsibility of the health care and public health communities to ensure that those treatments were safe and effective. The result was improvements to the regulatory process designed to accelerate access to and expedite approvals for drugs that treat a serious disease.

29 September 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JBJohn T. Brooks
John T. Brooks
PMPeter Marks
Peter Marks
RGRobert H. Goldstein
Robert H. Goldstein
RWRochelle P. Walensky
Rochelle P. Walensky
Intradermal vaccination delivers antigen into the space between the epidermis and the dermis. This space is an anatomically favorable site for immune stimulation, enriched in a heterogenous population of dendritic cells, macrophages, and monocytes that endow this tissue with a potent capacity to detect and respond robustly to immunologic stimuli, including those present in vaccines. For these reasons, the role of the dermis in adaptive immunity has been exploited for allergen testing and tuberculosis skin testing. And smallpox vaccination was developed by Jenner using something similar to intradermal administration: variolation, or the practice of scratching immunizing material into the skin.

13 April 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JJJefferson M. Jones
Jefferson M. Jones
BGBrian M. Gurbaxani
Brian M. Gurbaxani
AAAlice Asher
Alice Asher
SSStephanie Sansom
Stephanie Sansom
PAPallavi Annambhotla
Pallavi Annambhotla
SBSridhar V. Basavaraju
Sridhar V. Basavaraju
To reduce the risk of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) transmission through organ transplantation, donors are universally screened for these infections by nucleic acid tests (NAT). Deceased organ donors are classified as “increased risk” if they engaged in specific behaviors during the 12 months before death. We developed a model to estimate the risk of undetected infection for HIV, HBV, and HCV among NAT-negative donors specific to the type and timing of donors’ potential risk behavior to guide revisions to the 12-month timeline. Model parameters were estimated, including risk of disease acquisition for increased risk groups, number of virions that multiply to establish infection, virus doubling time, and limit of detection by NAT. Monte Carlo simulation was performed. The risk of undetected infection was <1/1 000 000 for HIV after 14 days, for HBV after 35 days, and for HCV after 7 days from the time of most recent potential exposure to the day of a negative NAT. The period during which reported donor risk behaviors result in an “increased risk” designation can be safely shortened.

15 July 2022 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
JOJeremy Otridge
Jeremy Otridge
COCynthia L Ogden
Cynthia L Ogden
KBKyle T Bernstein
Kyle T Bernstein
MKMartha Knuth
Martha Knuth
JFJulie Fishman
Julie Fishman
JBJohn T Brooks
John T Brooks
Background: Preprints are publicly available manuscripts posted to various servers that have not been peer reviewed. Although preprints have existed since 1961, they have gained increased popularity during the COVID-19 pandemic due to the need for immediate, relevant information. Objective: The aim of this study is to evaluate the publication rate and impact of preprints included in the Centers for Disease Control and Prevention (CDC) COVID-19 Science Update and assess the performance of the COVID-19 Science Update team in selecting impactful preprints. Methods: All preprints in the first 100 editions (April 1, 2020, to July 30, 2021) of the Science Update were included in the study. Preprints that were not published were categorized as “unpublished preprints.” Preprints that were subsequently published exist in 2 versions (in a peer-reviewed journal and on the original preprint server), which were analyzed separately and referred to as “peer-reviewed preprint” and “original preprint,” respectively. Time to publish was the time interval between the date on which a preprint was first posted and the date on which it was first available as a peer-reviewed article. Impact was quantified by Altmetric Attention Score and citation count for all available manuscripts on August 6, 2021. Preprints were analyzed by publication status, publication rate, preprint server, and time to publication. Results: Of the 275 preprints included in the CDC COVID-19 Science Update during the study period, most came from three servers: medRxiv (n=201, 73.1%), bioRxiv (n=41, 14.9%), and SSRN (n=25, 9.1%), with 8 (2.9%) coming from other sources. Additionally, 152 (55.3%) were eventually published. The median time to publish was 2.3 (IQR 1.4-3.7). When preprints posted in the last 2.3 months were excluded (to account for the time to publish), the publication rate was 67.8%. Moreover, 76 journals published at least one preprint from the CDC COVID-19 Science Update, and 18 journals published at least three. The median Altmetric Attention Score for unpublished preprints (n=123, 44.7%) was 146 (IQR 22-552) with a median citation count of 2 (IQR 0-8); for original preprints (n=152, 55.2%), these values were 212 (IQR 22-1164) and 14 (IQR 2-40), respectively; for peer-review preprints, these values were 265 (IQR 29-1896) and 19 (IQR 3-101), respectively. Conclusions: Prior studies of COVID-19 preprints found publication rates between 5.4% and 21.1%. Preprints included in the CDC COVID-19 Science Update were published at a higher rate than overall COVID-19 preprints, and those that were ultimately published were published within months and received higher attention scores than unpublished preprints. These findings indicate that the Science Update process for selecting preprints had a high fidelity in terms of their likelihood to be published and their impact. The incorporation of high-quality preprints into the CDC COVID-19 Science Update improves this activity’s capacity to inform meaningful public health decision-making.

21 October 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Closed access
SOSiobhán M O’cOnnor
Siobhán M O’cOnnor
RSRuiguang Song
Ruiguang Song
AVAlexander Viguerie
Alexander Viguerie
KBKate Buchacz
Kate Buchacz
CLCynthia M Lyles
Cynthia M Lyles
JBJohn T Brooks
John T Brooks
Background: People with diagnosed HIV (PWDH) live longer but have increased co-morbidities than peers without HIV and premature ageing. In 2021, 54% of United States PWDH were aged ≥50 years. PWDH age distribution projections beyond 2030 are needed to plan future HIV and ageing care. Methods: Our life table-based model used 2020–2021 Centers for Disease Control and Prevention National HIV Surveillance System data to project PWDH age distributions from 2021–2040 across three modeled scenarios, varying annual percentage change (APC) in HIV diagnoses (new infections proxy) and PWDH mortality rate. Results: The median age of PWDH increased from 51 years (2021) to 55–60 years (2040) when diagnoses decreased. Numbers of older PWDH increased across racial/ethnic groups and regions, regardless of decreasing or increasing diagnoses or reducing mortality. Reducing diagnoses 90% by 2040 with reduced mortality estimated 75% (695 912) of PWDH would be aged ≥50 years, 42% (388 639) aged ≥65 years, and 20% (190 600) aged ≥75 years. Extending −3% APC reductions in diagnoses projected 64% (670 977) aged ≥50 years, 33% (350 025) aged ≥65 years, and 16% (168 139) aged ≥75 years. Modestly increasing diagnoses projected 53% (761 194) aged ≥50 years, 26% (371 244) aged ≥65 years, and 12% (171 233) aged ≥75 years. Across scenarios, the number of PWDH aged ≥50, ≥65, and ≥75 years, respectively, increased 18%–34%, 144%–171%, and 565%–654%. Conclusions: By 2040, the estimated number of older PWDH will increase substantially, regardless of decreasing or increasing HIV diagnoses. The healthcare sector must prepare now to ensure future ageing-related care needs of PWDH are met.

1 March 2019 in Annals of Epidemiology
Verified
Journal Article
Open access
HBHeather Bradley
Heather Bradley
KAKeri N. Althoff
Keri N. Althoff
KBKate Buchacz
Kate Buchacz
JBJohn T. Brooks
John T. Brooks
MGM. John Gill
M. John Gill
EREli S. Rosenberg
Eli S. Rosenberg
To assess sampling bias in national viral suppression (VS) estimates derived from the Medical Monitoring Project (MMP) resulting from use of an abbreviated (four-month) annual sampling period. We aimed to improve VS estimates using cohort data from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) and a novel cohort-adjustment method. Using full calendar years of NA-ACCORD data, we assessed timing of HIV care attendance (inside vs. exclusively outside MMP's four-month sampling period), VS status at last test (<200 vs. ≥200 copies/mL), and associated demographics. These external estimates were used to standardize MMP to NA-ACCORD data with multivariable regression models of care attendance and VS, yielding adjusted 2009-2013 VS estimates with 95% confidence intervals. Weighted percentages of VS among persons in HIV care were 67% in 2009 and 77% in 2013. These estimates are slightly lower than previously published MMP estimates (72% and 80% in 2009 and 2013, respectively). The number of persons receiving HIV care was previously underestimated by 20%, because patients receiving care exclusively outside the MMP sampling period did not contribute toward the weighted population estimate. Careful examination of national surveillance estimates using data triangulation and novel methodologies can improve the robustness of VS estimates.